Currently, there are 537.50M common shares owned by the public and among those 536.14M shares have been available to trade.
The company’s stock has a 5-day price change of -5.33% and -15.82% over the past three months. AMGN shares are trading -3.37% year to date (YTD), with the 12-month market performance up to 2.15% higher. It has a 12-month low price of $257.80 and touched a high of $346.85 over the same period. AMGN has an average intraday trading volume of 2.63 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -5.88%, -10.27%, and -8.94% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of AMGEN Inc (NASDAQ: AMGN) shares accounts for 78.00% of the company’s 537.50M shares outstanding.
It has a market capitalization of $149.61B and a beta (3y monthly) value of 0.55. The stock’s trailing 12-month PE ratio is 35.64, while the earnings-per-share (ttm) stands at $7.81. The company has a PEG of 7.13 and a Quick Ratio of 0.96 with the debt-to-equity ratio at 8.02. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.27% over the week and 2.86% over the month.
Earnings per share for the fiscal year are expected to increase by 4.96%, and 5.74% over the next financial year. EPS should grow at an annualized rate of 5.00% over the next five years, compared to -0.22% over the past 5-year period.
Citigroup coverage for the AMGEN Inc (AMGN) stock in a research note released on November 14, 2024 offered a Neutral rating with a price target of $335. Bernstein was of a view on October 17, 2024 that the stock is Outperform, while Truist gave the stock Hold rating on October 14, 2024, issuing a price target of $320- $333. Cantor Fitzgerald on their part issued Overweight rating on September 27, 2024.
